Medicine:ABNCoV2
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | vlp |
| Clinical data | |
| Routes of administration | Intramuscular |
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.[1][2][3][4]
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[5]
References
- ↑ "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". 8 March 2021. https://www.bavarian-nordic.com/investor/news/news.aspx?news=6178.
- ↑ Clinical trial number NCT04839146 for "Safety and Tolerability of ABNCoV2 (COUGH-1)" at ClinicalTrials.gov
- ↑ "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. https://view.news.eu.nasdaq.com/view?id=b2990620f9697f3fecb6a816bdbc726c9&lang=en.
- ↑ Clinical trial number NCT05077267 for "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects" at ClinicalTrials.gov
- ↑ "Foreløbige resultater: Dansk vaccine virker i første forsøg med mennesker – og den virker godt" (in da). 2021-08-09. https://www.berlingske.dk/content/item/1582503.
 |
